JP7359449B2 - オーリスタチンｅ誘導体のアルブミン結合プロドラッグ - Google Patents

オーリスタチンｅ誘導体のアルブミン結合プロドラッグ Download PDF

Info

Publication number
JP7359449B2
JP7359449B2 JP2020529313A JP2020529313A JP7359449B2 JP 7359449 B2 JP7359449 B2 JP 7359449B2 JP 2020529313 A JP2020529313 A JP 2020529313A JP 2020529313 A JP2020529313 A JP 2020529313A JP 7359449 B2 JP7359449 B2 JP 7359449B2
Authority
JP
Japan
Prior art keywords
cancer
carcinoma
group
sulf07
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020529313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505541A (ja
JP2021505541A5 (https=
Inventor
フェリクス クラッツ，
アジャアジャ， ハーリド アブ
アナ ワルネッケ，
フリーデリーケ イー． ノルマン，
シュテファン ダーヴィト ケスター，
フェルナンデス， ハビエル ガルシア
ララ ペス，
ハイディ－クリスティン ヴァルター，
ヨハネス パル マグヌソン，
セルゲイ チェルへジャ，
ガラン， パトリシア ぺレス
フェデリコ メダ，
シュテフェン ヨゼフ ダウム，
Original Assignee
センチュリオン バイオファーマ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センチュリオン バイオファーマ コーポレイション filed Critical センチュリオン バイオファーマ コーポレイション
Publication of JP2021505541A publication Critical patent/JP2021505541A/ja
Publication of JP2021505541A5 publication Critical patent/JP2021505541A5/ja
Application granted granted Critical
Publication of JP7359449B2 publication Critical patent/JP7359449B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020529313A 2017-11-30 2018-11-30 オーリスタチンｅ誘導体のアルブミン結合プロドラッグ Active JP7359449B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762592721P 2017-11-30 2017-11-30
US62/592,721 2017-11-30
PCT/US2018/063376 WO2019108974A1 (en) 2017-11-30 2018-11-30 Albumin-binding prodrugs of auristatin e derivatives

Publications (3)

Publication Number Publication Date
JP2021505541A JP2021505541A (ja) 2021-02-18
JP2021505541A5 JP2021505541A5 (https=) 2022-01-11
JP7359449B2 true JP7359449B2 (ja) 2023-10-11

Family

ID=64744961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020529313A Active JP7359449B2 (ja) 2017-11-30 2018-11-30 オーリスタチンｅ誘導体のアルブミン結合プロドラッグ

Country Status (15)

Country Link
US (1) US11377473B2 (https=)
EP (2) EP3717503B1 (https=)
JP (1) JP7359449B2 (https=)
KR (1) KR20200118408A (https=)
CN (2) CN111712511B (https=)
AU (1) AU2018375787B2 (https=)
BR (1) BR112020009836A2 (https=)
DK (1) DK3717503T3 (https=)
ES (1) ES2970618T3 (https=)
IL (1) IL274919B2 (https=)
MX (1) MX2020005658A (https=)
NZ (1) NZ764948A (https=)
PT (1) PT3717503T (https=)
WO (1) WO2019108974A1 (https=)
ZA (1) ZA202002951B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11384104B2 (en) 2015-06-19 2022-07-12 Centurion Biopharma Corporation Delivery systems for controlled drug release
IL305268A (en) 2017-11-30 2023-10-01 Centurion Biopharma Corp Maytansinoid-based drug delivery systems
CN113321698B (zh) * 2020-02-28 2022-08-23 国家纳米科学中心 一种单甲基澳瑞他汀e前药及其制备方法和应用
KR20230012592A (ko) * 2020-05-19 2023-01-26 르 라보레또레 쎄르비에르 파라-아미노-벤질 링커, 이의 제조 방법 및 컨쥬게이트에서의 이의 용도
CN115969986A (zh) * 2022-12-30 2023-04-18 上海药明生物技术有限公司 羟丙基β环糊精稳定MMAE类抗体药物偶联物制剂的应用
WO2024230301A1 (zh) * 2023-05-09 2024-11-14 诺灵生物医药科技(北京)有限公司 一种抗体偶联药物及其用途
CN116813569B (zh) * 2023-07-10 2024-07-02 衡阳市中心医院 一种抗癌药中间体的制备方法和抗癌药的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004531544A (ja) 2001-04-30 2004-10-14 シアトル ジェネティクス，インコーポレーテッド ペンタペプチド化合物及びそれに関する使用
WO2016205738A2 (en) 2015-06-19 2016-12-22 Cytrx Corporation Delivery systems for controlled drug release
JP2017506628A (ja) 2014-02-07 2017-03-09 センター ナショナル ド ラ ルシェルシュ サイエンティフィーク がん及び炎症性疾患の治療のための結合体及びプロドラッグ

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125704A (en) 1977-09-14 1978-11-14 Sri International Phenyl-substituted rubidazone analogs
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US4966999A (en) 1988-06-07 1990-10-30 Cytogen Corporation Radiohalogenated compounds for site specific labeling
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
WO2005055939A2 (en) 2003-12-04 2005-06-23 Amr Technology, Inc. Vinca derivatives
SI2032606T1 (sl) * 2006-05-30 2014-02-28 Genentech, Inc. Protitelesa in imunokonjugati in njihove uporabe
JP5634862B2 (ja) 2007-05-16 2014-12-03 カーテーベー トゥモーアフォルシュングス ゲゼルシャフト ミット ベシュレンクテル ハフツング 低粘度アントラサイクリン製剤
EP2289558A1 (en) 2009-08-25 2011-03-02 KTB Tumorforschungsgesellschaft mbH Bisphosphonate-prodrugs
EP2630971B8 (en) 2012-02-21 2017-12-13 Vergell Medical S.A. Combinations of albumin-based drug delivery systems
US20140221429A1 (en) 2013-02-04 2014-08-07 Saud Ibrahim Al-Resayes Heterocyclic schiff's bases as novel and new antiglycation agents
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
JP6908964B2 (ja) * 2013-10-18 2021-07-28 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Ｐｓｍａリガンドコンジュゲートによる併用療法
MX2017004580A (es) * 2014-10-10 2017-06-27 Pfizer Combinaciones de auristatina sinergica.
AU2016280696B2 (en) 2015-06-15 2021-11-18 Abbott Diabetes Care Inc. Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same
IL305268A (en) 2017-11-30 2023-10-01 Centurion Biopharma Corp Maytansinoid-based drug delivery systems
US11632502B2 (en) 2021-09-10 2023-04-18 Pixart Imaging Inc. Optical sensor cancelling image flicker

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004531544A (ja) 2001-04-30 2004-10-14 シアトル ジェネティクス，インコーポレーテッド ペンタペプチド化合物及びそれに関する使用
JP2017506628A (ja) 2014-02-07 2017-03-09 センター ナショナル ド ラ ルシェルシュ サイエンティフィーク がん及び炎症性疾患の治療のための結合体及びプロドラッグ
WO2016205738A2 (en) 2015-06-19 2016-12-22 Cytrx Corporation Delivery systems for controlled drug release

Also Published As

Publication number Publication date
EP4344747A2 (en) 2024-04-03
JP2021505541A (ja) 2021-02-18
IL274919B2 (en) 2025-05-01
CN111712511B (zh) 2024-07-16
ES2970618T3 (es) 2024-05-29
EP3717503B1 (en) 2023-11-08
AU2018375787A1 (en) 2020-06-18
US11377473B2 (en) 2022-07-05
DK3717503T3 (da) 2024-01-22
BR112020009836A2 (pt) 2020-10-13
NZ764948A (en) 2024-08-30
ZA202002951B (en) 2023-10-25
CN118852324A (zh) 2024-10-29
WO2019108974A1 (en) 2019-06-06
AU2018375787B2 (en) 2023-02-23
US20200385421A1 (en) 2020-12-10
MX2020005658A (es) 2020-11-11
EP4344747A3 (en) 2024-07-03
PT3717503T (pt) 2024-01-16
RU2020121451A (ru) 2021-12-30
IL274919B1 (en) 2025-01-01
CA3083983A1 (en) 2019-06-06
IL274919A (en) 2020-07-30
KR20200118408A (ko) 2020-10-15
CN111712511A (zh) 2020-09-25
EP3717503A1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
JP7359449B2 (ja) オーリスタチンｅ誘導体のアルブミン結合プロドラッグ
JP7595098B2 (ja) 薬物制御放出のための送達系
JP2023164604A (ja) メイタンシノイド系薬物送達システム
RU2795101C2 (ru) Альбумин-связывающие пролекарства на основе производных ауристатина е
HK40110772A (en) Albumin-binding prodrugs of auristatin e derivatives
CA3083983C (en) Albumin-binding prodrugs of auristatin e derivatives
HK40040808B (en) Albumin-binding prodrugs of auristatin e derivatives
HK40040808A (en) Albumin-binding prodrugs of auristatin e derivatives
RU2783076C2 (ru) Системы доставки лекарств на основе майтанзиноида
HK40069235A (en) Delivery systems for controlled drug release
BR112017027445B1 (pt) Compostos, composição farmacêutica e uso dos mesmos para tratar um câncer, uma doença viral, uma doença autoimune, uma doença inflamatória aguda ou crônica e uma doença causada por bactérias, fungos, ou outros micro-organismos
HK1254624B (en) Delivery systems for controlled drug release

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230822

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230921

R150 Certificate of patent or registration of utility model

Ref document number: 7359449

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350